ArticleIranian biomedical journal2026
Biotechnological Approaches to Probiotics and Postbiotics through the Gut-Brain Axis Modulation.
Article in Iranian biomedical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiome and gut-brain axis are central to systemic homeostasis, with dysbiosis implicated in neurodegenerative (Alzheimer's and Parkinson's) disorders and gastrointestinal conditions (inflammatory bowel disease, irritable bowel syndrome, and fibromyalgia). These conditions are marked by a reduction in beneficial taxa (e.g., Faecalibacterium prausnitzii and Bifidobacterium) and an increase in harmful ones (e.g., Escherichia coli and Clostridium scindens). Probiotic, prebiotic, postbiotic, and symbiotic interventions show therapeutic promise, but results can vary. Biotechnological advances, including CRISPR-Cas9 and genetic kill-switch systems, enable precision-engineered probiotics and postbiotics, though concerns about safety, genetic stability, gene transfer, and immune compatibility persist. Encapsulation and nanoencapsulation strategies improve microbial viability and site-specific delivery; i.e., microencapsulating Lactobacillus acidophilus and Bifidobacterium animalis in alginate-pectin matrices enhances survival during freeze-drying, storage, and gastrointestinal transit. Advancing clinical translation requires integrating multi-omics and machine learning with bioengineering approaches. This review examines the microbial-neural interface and surveys emerging biotechnological strategies for improving microbial-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.